Vistagen Therapeutics, Inc. (VTGN)
CIK 1411685 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 44.4M shares as of Aug 10, 2026 (10-Q). Share count fell from 219.3M to 7.9M between Feb 7, 2023 and Jun 22, 2023, a pattern consistent with a reverse split (roughly 1-for-28); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| T2 Warrants | 11.3M | $8.877 | — | — |
| Warrants Expiring October42028 | 11.3M | $8.877 | — | — |
| T1 Warrants | 9.3M | $5.38 | — | — |
| Warrants With Exercise Price Of5.380 | 9.3M | $5.38 | — | — |
| Prefunded Warrants | 3.6M | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 20.6M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $7.3 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $424,100 as of Mar 31, 2013.
Rough fully diluted estimate: 64.9M = 44.4M O/S + 20.6M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 14, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 44.4M | Aug 10, 2026 |
| + T2 Warrants (if exercised) | 11.3M | Oct 2, 2023 |
| + Warrants Expiring October42028 (if exercised) | 11.3M | Jun 30, 2026 |
| + T1 Warrants (if exercised) | 9.3M | Oct 2, 2023 |
| + Warrants With Exercise Price Of5.380 (if exercised) | 9.3M | Jun 30, 2026 |
| + Prefunded Warrants (if exercised) | 3.6M | Oct 2, 2023 |
| Fully diluted estimate | 89.1M | +100.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 0 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full VTGN workspace